Balance Sheet Protagonist Therapeutics, Inc.
Equities
PTGX
US74366E1029
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.25 USD | +0.67% |
|
+5.38% | +133.81% |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 117M | 124M | 126M | 187M | 97.25M | |||||
Short Term Investments | 188M | 203M | 112M | 155M | 322M | |||||
Total Cash And Short Term Investments | 306M | 327M | 237M | 342M | 419M | |||||
Accounts Receivable, Total | 2.43M | 1.57M | 10K | 10M | 165M | |||||
Other Receivables | 1.4M | 3.77M | 42K | 332K | 3.49M | |||||
Total Receivables | 3.82M | 5.33M | 52K | 10.33M | 168M | |||||
Prepaid Expenses | 5.97M | 8.5M | 5.67M | 3.63M | 4.24M | |||||
Restricted Cash | 10K | - | - | - | - | |||||
Other Current Assets, Total | - | - | - | - | - | |||||
Total Current Assets | 316M | 341M | 243M | 356M | 592M | |||||
Gross Property Plant And Equipment | 9.88M | 10.99M | 9.88M | 8.38M | 19.64M | |||||
Accumulated Depreciation | -3.47M | -4.26M | -5.25M | -6.23M | -7.04M | |||||
Net Property Plant And Equipment | 6.41M | 6.73M | 4.63M | 2.15M | 12.61M | |||||
Long-term Investments | 2M | - | - | - | 140M | |||||
Deferred Tax Assets Long-Term | - | - | - | - | - | |||||
Other Long-Term Assets, Total | 450K | 225K | 225K | 225K | 225K | |||||
Total Assets | 324M | 348M | 248M | 358M | 745M | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 3.08M | 1.6M | 3.64M | 772K | 1.62M | |||||
Accrued Expenses, Total | 18.42M | 37.31M | 24.54M | 19.26M | 23.62M | |||||
Current Portion of Leases | 1.46M | 2.2M | 2.52M | 1.14M | 510K | |||||
Current Income Taxes Payable | - | - | - | - | 2.69M | |||||
Unearned Revenue Current, Total | 14.48M | 1.6M | - | - | 18.89M | |||||
Other Current Liabilities | 2.81M | 1.31M | 484K | 102K | 74K | |||||
Total Current Liabilities | 40.24M | 44.02M | 31.18M | 21.27M | 47.4M | |||||
Long-Term Debt | - | - | - | - | - | |||||
Long-Term Leases | 4.5M | 3.66M | 1.14M | - | 10.36M | |||||
Unearned Revenue Non Current | - | - | - | - | 11.68M | |||||
Other Non Current Liabilities | 121K | - | - | - | - | |||||
Total Liabilities | 44.86M | 47.67M | 32.32M | 21.27M | 69.43M | |||||
Preferred Stock Convertible | - | - | - | - | - | |||||
Preferred Stock - Others | - | - | - | - | - | |||||
Total Preferred Equity | - | - | - | - | - | |||||
Common Stock, Total | - | - | - | 1K | 1K | |||||
Additional Paid In Capital | 563M | 710M | 753M | 952M | 1.02B | |||||
Retained Earnings | -284M | -409M | -537M | -616M | -341M | |||||
Comprehensive Income and Other | 28K | -299K | -359K | -105K | -82K | |||||
Total Common Equity | 280M | 300M | 216M | 337M | 675M | |||||
Total Equity | 280M | 300M | 216M | 337M | 675M | |||||
Total Liabilities And Equity | 324M | 348M | 248M | 358M | 745M | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 43.81M | 48.41M | 51.28M | 58.27M | 61.38M | |||||
ECS Total Common Shares Outstanding | 43.75M | 47.84M | 49.34M | 57.71M | 61.04M | |||||
Book Value / Share | 6.39 | 6.27 | 4.37 | 5.83 | 11.06 | |||||
Tangible Book Value | 280M | 300M | 216M | 337M | 675M | |||||
Tangible Book Value Per Share | 6.39 | 6.27 | 4.37 | 5.83 | 11.06 | |||||
Total Debt | 5.96M | 5.86M | 3.66M | 1.14M | 10.87M | |||||
Net Debt | -302M | -321M | -234M | -340M | -548M | |||||
Debt Equivalent Oper. Leases | 13.48M | 14.97M | 17.7M | 17.58M | 19.81M | |||||
Account Code - Inventory Valuation | 3 | - | 3 | 3 | 3 | |||||
Machinery, Total | 4.19M | 5.18M | 5.91M | 6.47M | 7.8M | |||||
Full Time Employees | 79 | 118 | 105 | 112 | 126 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















